What’s are Pharmaceutical Companies doing to Move into the Cannabis Industry?
As we know, the DEA is sticking to its erroneous and outdated theory that cannabis has no medical use.
So, what’s a pharmaceutical company supposed to do?
Go elsewhere, of course
Some have started to research and develop drugs in labs north of the border while some have gone down to Colombia where they’re growing their own. Still others are getting approval in Europe and hoping that validation gives them an edge when they undertake the fastidious FDA approval process, according to a report in UK Business Insider.
While they may be as greedy as ever, pharmaceutical companies are at least open to scientific experimentation. And they’re not interested in missing the medical marijuana boat.
Toronto-based Avicanna, which focuses on MMJ, now has access to lab space in the JLabs ecosystem as well as the recognition they need to recruit top-notch scientists and researchers. In exchange, Johnson & Johnson gets a chance to work with an innovative company that they can invest in when they see fit.
Other pharmaceutical companies are looking to study cannabis by importing extracts, but so far only one cannabis-based drug has FDA and DEA approval: dronabinol (or Marinol), which is designed to treat some of the negative side-effects of chemotherapy and AIDS.
American researchers who want to grow marijuana need to apply to the DEA for a license in a complex process that can take years.
Instead of leading this important medical cannabis process, the US is falling behind.